gms | German Medical Science

56. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)
3èmes journées françaises de Neurochirurgie (SFNC)

Deutsche Gesellschaft für Neurochirurgie e. V.
Société Française de Neurochirurgie

07. bis 11.05.2005, Strasbourg

Complete remission of advanced autologous intracranial gliomas by oncolytic Parvovirus H-1

Vollständige Remission fortgeschrittener autologer intrakranieller Gliome nach Therapie mit dem onkolytischen Parvovirus H-1

Meeting Abstract

  • corresponding author K. Geletneky - Department of Neurosurgery, University of Heidelberg
  • M. Herrero y Calle - Department of Neurosurgery, University of Freiburg
  • C. Herold-Mende - Department of Neurosurgery, University of Heidelberg
  • C. Sommer - Department of Neuropathology, University of Ulm
  • R. Koch - German Cancer Research Center
  • J. R. Schlehofer - German Cancer Research Center
  • J. Rommelaere - German Cancer Research Center

Deutsche Gesellschaft für Neurochirurgie. Société Française de Neurochirurgie. 56. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), 3èmes journées françaises de Neurochirurgie (SFNC). Strasbourg, 07.-11.05.2005. Düsseldorf, Köln: German Medical Science; 2005. Doc10.05.-08.02

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dgnc2005/05dgnc0121.shtml

Veröffentlicht: 4. Mai 2005

© 2005 Geletneky et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective

Virotherapy of malignant gliomas is an alternative strategy to improve the prognosis of this rapidly fatal disease. The oncolytic and non-pathogenic Parvovirus H-1 possesses strong cytotoxic effects in glioma cells in vitro. In this study, we investigated the therapeutic potential of H-1 virus in a glioma model in immunocompetent rats.

Methods

RG-2 rat gliomas were implanted into immunocompetent animals. MRI was performed to demonstrate tumour growth. When tumours had reached a size of >6mm in the largest diameter, animals received intratumoural stereotactic injection of H-1 virus (n=12) or sham-operation (n=12). Treatment effects were monitored by MRI. When animals were sacrificed, PCR, histology and immunostaining of brain tissue were performed.

Results

H-1 virus treatment of animals with large intracranial gliomas resulted in rapid tumour regression in 8 animals. 4 of the animals were sacrificed prior to complete tumour remission. Histology showed widespread destruction of the tumour tissue, but no toxic or inflammatory side effects in the surrounding brain tissue. Viral proteins could be demonstrated by immunostaining. The remaining 4 animals survived for >1 year without tumour recurrence. All control animals died within 22 days. The difference between the survival time of H-1 therapy group and control group were statistically signifcant (logrank test: p<0.001).

Conclusions

Parvovirus H-1 possesses strong antitumour activity in glioma cells in vivo. This finding and the absence of pathogenic side effects make H-1 virus a promising candidate for oncolytic virotherapy of malignant gliomas.